www.fdanews.com/articles/197985-clover-biopharmaceuticals-gets-66-million-from-cepi-for-covid-19-vaccine-trial
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
Clover Biopharmaceuticals Gets $66 Million from CEPI for COVID-19 Vaccine Trial
July 9, 2020
Chinese drugmaker Clover Biopharmaceuticals received a $66 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) to support clinical development and manufacturing of its COVID-19 vaccine candidate.
The funding will support early testing and the preparation of sites for a global efficacy trial. CEPI anticipates providing more funding if the early stage clinical development is successful.
Clover’s S-Trimer is “a promising vaccine candidate with the potential to be scaled up to produce hundreds of millions or even one billion doses per year,” said CEPI’s CEO Richard Hatchett.